Ortin Global share price
NSE: ORTINGLOBEBSE: 539287Pharmaceuticals & BiotechnologySmall Cap
Formerly Ortin Laboratories
Last close ₹12.84down ₹0.48 (3.60%)BSE ₹13.00
Share price at the NSE close on 23 Oct 2026. Previous close ₹13.32.
52-week range of traded prices to 23 Oct 2026
₹10.66Low, 28 Oct 2025₹21.30High, 9 Jun 2026
- Under NSE's graded surveillance, stage 0, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹10 Cr4,502nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 May 2026
- 8.4
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 Aug 2026
- −56.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- −52.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 May 2026
- 0.81
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 14,54557.7% delivered
Results
Standalone; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 14 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹0.01 Crdown 66.28%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹0.34 CrQuarter to Mar 2026: −₹0.01 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- −2,912.9%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 6 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2018, the company's revenue for that year, ₹77 Cr, differs from its quarters added, ₹80 Cr. From the year to Mar 2021, the company's revenue for that year, ₹8.17 Cr, differs from its quarters added, ₹209 Cr.
| ₹ crore | Sep 2024Filed 14 Nov | Dec 2024Filed 12 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 14 Aug | Sep 2025Filed 14 Nov | Dec 2025Filed 14 Feb | Mar 2026Filed 30 May | Jun 2026Filed 14 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.05 | 0.03 | 0.05 | 0.04 | 0.01 | 0.01 | 0.03 | 0.01 |
| Net profit | −0.47 | −0.11 | −0.16 | −0.18 | −0.50 | −0.05 | −0.01 | −0.34 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | −862.0% | −319.1% | −362.3% | −440.7% | −3,589.3% | −432.5% | −27.0% | −2,912.9% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, DRUGS AND MEDICINES, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: loss, last twelve months. Not shown, EV/EBITDA: operating loss, last twelve months. Dividend yield is not shown: no dividend in the years on record. Its history crosses a change of basis in the accounts in the years to Mar 2018 and Mar 2021: days before it are of the company before the change.PE ratio and valuation history
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 89% of 1,805 trading days since Nov 2018.
LowestHighest
Its median1.7Industry median2.8
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +38.4% | – | – | 0.0% |
| 3 years | −8.2% | – | – | 0.0% |
| 5 years | −15.2% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 3 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Ortin Global in market cap. 2 companies in the table last traded before then: their rows are priced on their last trade.
Ortin Global is not on the chart: it has no P/E today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Desh Rakshak AushdhalayaDESHRAK | 15 | 27.8 | 1.2 | 13.0 | −24.3% | – | 4.7% | 5.8% | 0.00% |
| Mono PharmacareMONOPHARMA | 15 | 42.4 | 0.5 | – | −1.6% | −88.3% | 1.1% | – | 0.00% |
 Beryl DrugsBERLDRG | 13 | 20.1 | 1.3 | 8.1 | +8.3% | +169.1% | 6.4% | 3.1% | 0.00% |
 Unjha FormulationsUNJHAFOR | 12 | 26.2 | 3.2 | 14.6 | +13.0% | +386.7% | 13.5% | 15.2% | 0.00% |
 Dipna PharmachemDPL | 10 | – | – | – | – | – | – | – | 0.00% |
 Adline Chem LabADLINE | 9 | – | – | – | – | – | – | −685.2% | 0.00% |
 Brawn BiotechBRAWN | 8 | 8.9 | 1.8 | – | +13.6% | – | 22.3% | −12.6% | 0.00% |
 Vivanza BiosciencesVIVANZA | 6 | 14.1 | 1.5 | 32.8 | +735.0% | – | 10.9% | 3.3% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
8 Sep · Management
7 Sep · Board meeting
Aug 2026
Ortin Global share price by year
Each calendar year to 2025.Ortin Global share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 13.81 | −22.0% | 18.07 | 9.79 |
| 2024 | 17.71 | −23.3% | 23.48 | 16.75 |
| 2023 | 23.10 | −2.7% | 27.65 | 16.95 |
| 2022 | 23.75 | −28.7% | 35.15 | 20.25 |
| 2021BSE close | 33.30 | +13.1% | 46.55 | 21.85 |
| 2020BSE close | 29.45 | +203.3% | 29.45 | 7.13 |
| 2019BSE close | 9.71 | −38.7% | 16.82 | 8.52 |
| 2018BSE close | 15.85 | −48.1% | 30.90 | 14.00 |
| 2017BSE close | 30.55 | +52.4% | 32.70 | 15.00 |
| 2016BSE close | 20.05 | −37.0% | 33.85 | 13.90 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 13.60 | 13.60 | 12.10 | 12.84 | 12.69 | 14,545 | 57.7% |
| 22 Oct 2026 | 13.56 | 14.63 | 13.11 | 13.32 | 13.66 | 4,658 | 85.8% |
| 21 Oct 2026 | 14.56 | 14.56 | 13.11 | 13.53 | 13.50 | 4,887 | 76.4% |
| 19 Oct 2026 | 14.35 | 14.45 | 14.35 | 14.42 | 14.39 | 3,320 | 54.8% |
| 16 Oct 2026 | 14.30 | 15.23 | 14.00 | 14.34 | 15.03 | 9,474 | 91.5% |
| 15 Oct 2026 | 14.38 | 15.29 | 14.00 | 14.30 | 14.50 | 7,612 | 66.6% |
| 14 Oct 2026 | 15.15 | 15.29 | 14.22 | 14.45 | 14.50 | 17,730 | 53.6% |
| 13 Oct 2026 | 15.00 | 15.29 | 14.20 | 15.28 | 15.08 | 11,679 | 99.6% |
| 12 Oct 2026 | 14.48 | 15.20 | 14.10 | 14.93 | 14.93 | 9,324 | 99.5% |
| 9 Oct 2026 | 14.67 | 14.67 | 13.50 | 13.83 | 14.33 | 11,036 | 82.7% |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- ORTIN GLOBAL LIMITED
- NSE symbol
- ORTINGLOBE
- BSE code
- 539287
- ISIN
- INE749B01020
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Aug 2015 on BSE, Mar 2021 on NSE
- Face value
- ₹10
- Former symbols
- ORTINLAB
- CIN
- L68200TG1986PLC006885
- Corporate identity number, the registrar of companies' code for it
Earlier listing: Ortin Laboratories Ltd-$ (BSE 590074), delisted on 30 Nov 2016.